source
- AstraZeneca attributes Phase 3 failure of bone disease enzyme therapy to trial design flawsAstraZeneca disclosed that its Phase 3 study of an enzyme replacement therapy for a rare genetic bone disorder did not meet its primary objectives. The company said the shortfall was largely due t…
- Endpoints Weekly releases 2026 Women in Biopharma list of 20 honorees after reviewing 200 nominationsEndpoints Weekly announced its annual Women in Biopharma 2026 project, highlighting leading women in the industry. The editorial team examined close to 200 nominations to select a shortlist. The…